Protean to Present Advanced AI Research at AACR22
Protean BioDiagnostics develops AI approach to detect specific EGFR mutations in lung cancer specimens using analysis of digital pathology images and will present findings at the AACR meeting.
Protean BioDiagnostics will present innovative data demonstrating the ability of properly trained AI systems to accurately detect the presence of specific DNA mutations using digital pathology.
The analysis of lung cancer for the presence of DNA mutations is now indicated in all lung cancer patients due to the availability of effective anti-EGFR targeted therapies. Unfortunately not all patients receive EGFR testing due to many barriers. This is particularly true in resource poor environments. Protean BioDiagnostics has developed an innovative approach to detect underlying lung cancer mutations using only digital pathology images. This system could increase the speed of detection of EGFR mutation and improve access to anti-EGFR based therapy particularly in underserved and resource poor areas.
About Protean BioDiagnostics
Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support.
We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.